Home Newsfeeds Oppenheimer Upgrades Verizon Communications to Outperform, Announces $50 Price Target

Oppenheimer Upgrades Verizon Communications to Outperform, Announces $50 Price Target

Oppenheimer analyst Timothy Horan upgrades Verizon Communications (NYSE:VZ) from Perform to Outperform and announces $50 price target.

byBenzinga Newsdesk

October 6, 2022

1 minute read

Oppenheimer analyst Timothy Horan upgrades Verizon Communications (NYSE:VZ) from Perform to Outperform and announces $50 price target.

Analyst Ratings

Analyst Expectations For Celldex Therapeutics’s Future

By Benzinga Insights

June 3, 8:00 AM

Celldex Therapeutics (NASDAQ:CLDX) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from…

CLDX

Lake Street Maintains Buy on PAVmed, Lowers Price Target to $5

By Benzinga Newsdesk

August 17, 10:31 AM

Lake Street analyst Frank Takkinen maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $7 to $5.

PAVM

Telomir Pharmaceuticals’ To Present Pre-Clinical Data For Age-Reversal Drug Telomir-1 At The National Press Club In Washington, DC, On April 15, 2024

By Benzinga Newsdesk

April 2, 8:39 AM

Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomeraseNew York Times article supports

TELO

Solid Biosciences Granted FDA Orphan Drug Designation For Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003; Patient Dosing Expected To Begin Mid-To-Late Q1 2024

By Benzinga Newsdesk

January 16, 9:08 AM

– Patient dosing expected to begin mid-to-late Q1 2024 – CHARLESTOWN, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB), a life sciences company developing precision genetic medicines for

SLDB

Oppenheimer Upgrades Verizon Communications to Outperform, Announces $50 Price Target

Related Posts

Analyst Expectations For Celldex Therapeutics’s Future

Lake Street Maintains Buy on PAVmed, Lowers Price Target to $5

Telomir Pharmaceuticals’ To Present Pre-Clinical Data For Age-Reversal Drug Telomir-1 At The National Press Club In Washington, DC, On April 15, 2024

Solid Biosciences Granted FDA Orphan Drug Designation For Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003; Patient Dosing Expected To Begin Mid-To-Late Q1 2024